

Novel rehabilitation program after left ventricular assist device (LVAD) implantation improves functional tests and reduces levels of prognostic heart failure biomarkers

T. Chwyczo, L. Zalucka, E. Smolis-Bak, I. Kowalik, E. Noszczak, M. Bogucki, E. Piotrowicz, M. Sobieszczanska-Malek, T. Zielinski, J. Szymanski, J. Was, M. Kusmierczyk, R. Dabrowski, H. Szwed, R. Piotrowicz

National Institute of Cardiology, Warsaw, Poland

On behalf of RH-ROT

Funding Acknowledgement: Type of funding source: Public grant(s) – National budget only. Main funding source(s): National Center for Research and Development - STRATEGMED II project

Background: Rehabilitation after LVAD implantation is increasingly used. We developed the novel method of comprehensive rehabilitation starting directly after LVAD implantation.

Study group: 21 recent LVAD (15 Heart Mate III, 6 HeartWare) recipients (56.2±11.7 yrs, 100% men) were included to 5-week rehabilitation program, which included supervised endurance training on cycloergometer (5 times per week), resistance training, general fitness exercises with elements of equivalent and coordination exercises (every day). 6-minute walking test (6MWT), cardiopulmonary exercise test (CPET) and prognostic biomarkers: NT-proBNP, Galectin-3 and ST2 were investigated at the beginning and at the end of rehabilitation program.

Results: See Table 1.

At the end of rehabilitation program, significant increase in 6MWT distance, maximum workload, peak VO₂ and upward shift of anaerobic threshold in CPET were observed in all patients. Significant reductions of NTproBNP, ST2 and galectin-3 levels were observed. There were no major adverse events during rehabilitation.

Conclusions: Comprehensive novel rehabilitation in LVAD recipients is safe and results in significant improvement of 6-minutes walking test distance and cardiopulmonary exercise test results. Moreover, this novel rehabilitation program reduces levels of prognostic biomarkers of heart failure: NT-proBNP, Galectin-3 and ST2.

Results before and after rehabilitation

Parameter	Before (x ± SD)	After (x ± SD)	Delta [95% CI]	P
6MWT distance (m)	313.5±103.2	433.1±94.4	119.6 [83.1; 156.1]	<0.0001
Max workload (Watts)	42.6±12.4	61.6±16.0	19.0 [14.4; 23.6]	<0.0001
pVO ₂ (ml/kg/min)	11.2±2.1	13.2±2.4	2.0 [1.1; 2.9]	0.0002
pVO ₂ % predicted	39.4±11.3	46.4±11.5	7.0 [3.5; 10.6]	0.0006
AT (ml/kg/min)	9.0±1.8	10.8±2.1	1.8 [1.0; 2.6]	0.0002
Galectin-3	9.87±2.25	8.48±1.81	-1.39 [-2.22; -0.56]	0.0029
ST2	27.86±11.4	22.64±7.8	-5.22 [-9.5; -0.92]	0.0205
NTproBNP (pg/ml) median [Q1 –Q3]	4350 [2620–8476]	1201 [1048–2329]	-2621 [-4961; -1211]	<0.0001

6MWT, 6-minutes walking test; Max workload, maximum achieved workload on cycle ergometer; pVO₂, peak oxygen uptake; pVO₂% predicted, % of predicted peak oxygen uptake; AT, anaerobic threshold; NTproBNP, N-Terminal Pro-B-Type Natriuretic Peptide – medians and quartiles; Delta [95% CI], difference between the results before and after rehabilitation, 95% confidence interval is given in square brackets.